Navigation Links
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Date:2/3/2010

s of $24.3 million, or $0.60 per share, for the year ended December 31, 2008.  Revenues were $22.2 million for 2009, compared to $16.2 million in 2008. The increase in revenues for 2009 was primarily attributable to revenues from the Company's expanded agreement with Sigma-Aldrich. Total operating expenses were $41.6 million in both 2009 and 2008.

2009 Accomplishments and Recent Highlights

Therapeutic Programs and Research

  • Clinical Development Progress in Sangamo's Lead Therapeutic Program in DN and Renewed Program Support from JDRF: In January 2010, Sangamo initiated a Phase 2b trial of SB-509 in subjects with moderately severe DN.  The Juvenile Diabetes Research Foundation International (JDRF) also renewed its support for this program and will provide up to $3.0 million of funding for the trial. Sangamo's double blind, repeat-dosing, placebo controlled Phase 2b study, SB-509-901, is designed to finalize dose, schedule and primary and secondary approvable endpoints for pivotal Phase 3 trials.  Inclusion criteria for the trial are based upon accumulated data from Sangamo's earlier Phase 1 and Phase 2 clinical trials in subjects with DN that defined a drug-responsive population. The data included top-line, statistically significant data from the company's Phase 2 trial, SB-509-601, that established a mechanistic proof of concept for the neuroregenerative effects of SB-509 treatment as demonstrated by statistically significant increases in intraepidermal nerve fiber density (IENFD).  In addition, improvements in clinically relevant outcomes were observed in Neurologic Impairment Score of the Lower Limb
    '/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
2. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
4. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
8. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
9. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
10. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Enzyme for Pulp & Paper Industry Report ... The Global Enzyme for Pulp & Paper Industry Report ... current state of the global enzyme for pulp & ... overview of the industry including definitions, classifications, applications and ...
(Date:8/27/2014)... Palm Beach County, Florida (PRWEB) August 27, 2014 ... & Company Inc. (SCI) is announcing the creation ... board’s priority is to take the SCI’s philosophy ... insuring the company’s research and development actions are ... interpretations. , This new Scientific Advisory Board provides ...
(Date:8/27/2014)... College, PA (PRWEB) August 27, 2014 ... Simulation Software with new features for the biomedical ... is an enhanced Biological Thermal Sensor, exclusive to the ... a specialty version of XFdtd, developed to calculate the ... export functionality has been added to all versions to ...
(Date:8/26/2014)... 26, 2014  NeuroSigma, Inc., a Los ... bioelectronic technologies, today announced that it has filed a ... and Exchange Commission relating to a proposed initial public ... to be offered and the price range for the ... Jefferies LLC will act as the book-running manager for ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... 3 Sangamo BioSciences,Inc. (Nasdaq: SGMO ) announced ... will provide an update on the progress of,Sangamo,s ZFP ... strategy at 12:45pm (PT) on Wednesday, October 10, 2007,at ... will be webcast live and may be accessed via ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a biopharmaceutical ... candidates principally,for use in the hospital setting, announced ... will present the corporate overview on,Wednesday, October 10, ... Eastern Time),during the BIO Investor Forum in San ...
... Laboratories to 45%, GURGAON, India, Oct. 3 ... announced the,signing of Definitive Agreements, providing for an increase ... 45% at a price of Rs. 160 per share,aggregating ... of shares from the existing Promoters (b) Preferential ...
Cached Biology Technology:Sangamo BioSciences to Present at the 2007 BIO InvestorForum 2Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at BIO Investor Forum 2Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 2Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 3
(Date:8/27/2014)... Outstanding basic research, a growing focus on translating ... care have earned the Herbert Irving Comprehensive Cancer ... and NewYork-Presbyterian Hospital an $18 million, five-year Cancer ... (NCI). The grant renews the center,s status as ... in New York City and one of only ...
(Date:8/27/2014)... of studies have shown that excessive iron ... Parkinson,s disease. Previous studies from Chunyan Guo ... China have shown that baicalin prevented iron ... metal transporter 1 expression, and increased ferroportin ... rotenone-induced Parkinson,s disease rats. However, the relationship ...
(Date:8/27/2014)... ago the Happy Camp Complex of fires had consumed ... complex had consumed 35,530 as of eight hours ago. ... Happy Camp Ranger District of the Klamath National Forest ... 11, 2014. All but three of those fires are ... of contained fires and their size at containment: Delta, ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... The TWAS 22nd General Meeting will take place on ... Theoretical Physics (ICTP), home to the Academy,s secretariat. TWAS,s ... by Romain Murenzi, executive director of TWAS; Fernando Quevedo, ... Affairs, Italy; and Jacob Palis, TWAS President, will highlight ...
... American Heart Association will today present Gladstone Institutes ... PhD, with the 2011 AHA Distinguished Scientist Award, ... founding cardiovascular scientists. The Distinguished Scientist Award ... Association can give a scientist. Dr. Mahley is ...
... 2 million people each year, is caused primarily by infectious ... Mtb . Mtb targets human immune cells as ... body,s immune response. Up until now, scientists ... the Immunity and Infection Research Centre at Vancouver Coastal Health ...
Cached Biology News:TWAS 22nd General Meeting in Trieste 2Gladstone founder receives American Heart Association Distinguished Scientist Award 2Researchers uncover why the body can't defend against tuberculosis 2